A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Triple · Basic science
Enrollment
72actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic considerations
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-04 | actual | When the study began enrolling |
| Primary completion | 2025-09-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-03 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer
Interventions
- Drug: ABBV-1088
- Drug: Placebo for ABBV-1088
- Drug: Itraconazole (ITZ)
Primary outcomes
what the primary-completion date above is the date OFPart 1, 2 and 3: Maximum Plasma Concentration (Cmax) of ABBV-1088
measured Up to approximately 24 days
Part 1, 2 and 3: Time to Cmax (Tmax) of ABBV-1088
measured Up to approximately 24 days
Part 1, 2 and 3: Terminal Phase Elimination Rate Constant (Beta) of ABBV-1088
measured Up to approximately 24 days
Part 1, 2 and 3: Terminal Phase Elimination Half-Life (t1/2) of ABBV-1088
measured Up to approximately 24 days
Part 2 and 3: Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) of ABBV-1088
measured Up to approximately 24 days
Part 2 and 3: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf) of ABBV-1088
measured Up to approximately 24 days
Number of Participants with Adverse Events (AEs)
measured Up to approximately 54 days
Part 1: Trough Concentration (Ctrough) of ABBV-1088
measured Up to approximately 24 days
Part 1: Area Under the Plasma Concentration-time Curve (AUC) for the First and Final Dose Intervals (AUCtau)
measured Up to approximately 24 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed